Vireo Growth (FRA:K95) ROCE %: 2.16% (As of Mar. 2026)

What is Vireo Growth ROCE %?

Vireo Growth FRA:K95 -5.39% 44 ROCE % is 2.16% as of Mar. 2026. GuruFocus rates FRA:K95 with a GF Score™ of 44/100 and a GF Value™ of €7.54 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vireo Growth's annualized ROCE % for the quarter that ended in Mar. 2026 was 2.16%.

Vireo Growth (FRA:K95) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vireo Growth ROCE % Related Terms

Vireo Growth ROCE % Historical Data

* Premium members only.

The historical data trend for Vireo Growth's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vireo Growth ROCE % Chart

Vireo Growth Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-16.71

-10.33

19.61

19.44

-2.46

Vireo Growth Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															7.79	-3.45	-5.58	-2.95	2.16

44GF Score

Vireo Growth Inc FRA:K95

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vireo Growth ROCE % Calculation

Vireo Growth's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-8.247	/	( ( (266.314 - 129.371)	+	(697.85 - 163.565) )	/ 2 )
	=	-8.247	/	( (136.943	+	534.285)	/ 2 )
	=	-8.247	/	335.614
	=	-2.46 %

Vireo Growth's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	12.456	/	( ( (697.85 - 163.565)	+	(803.412 - 186.667) )	/ 2 )
	=	12.456	/	( ( 534.285	+	616.745 )	/ 2 )
	=	12.456	/	575.515
	=	2.16 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 2.16% mean?

Vireo Growth (FRA:K95) has a ROCE % of 2.16% as of Mar. 2026.

Is Vireo Growth's ROCE % too high?

Vireo Growth's current ROCE % is 2.16%. The Drug Manufacturers industry median ROCE % is 7.00. Vireo Growth's value of 2.16% is 69.1% below this industry median. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Vireo Growth's ROCE % compare to ZTS?

Vireo Growth's ROCE % of 2.16% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Vireo Growth's value of 2.16% is 69.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current ROCE % of 2.16% is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current ROCE % is 2.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vireo Growth stock overvalued right now?

Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current ROCE % is 2.16% and 69.1% below the Drug Manufacturers industry median of 7.00. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current ROCE % is 2.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vireo Growth (FRA:K95) Overvalued in 2026?

Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued. The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54. GuruFocus considers Vireo Growth to be Modestly Overvalued.

Key valuation signals for FRA:K95:

ROCE %: 2.16%
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
GF Score™: 44/100 with 6 warning signs
Industry Position: 69.1% below the Drug Manufacturers median

No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vireo Growth Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSX:GUD TSX:DHT.U TSX:WEED NEOE:VRNO XCNQ:CL TSX:CPH NEOE:GLAS.A.U TSX:TSND TSX:ACB TSX:OGI XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges VREOD:USA VREO:Canada

Address 207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402

Website https://www.vireogrowth.com

Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.

44GF Score

Get the complete analysis for FRA:K95

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.42

Price

€7.54

GF Value

View FRA:K95 Analysis

See ROCE % data for all stocks →